Physician profile
Wes A Allison
NPI 1417084351
$3,888.54
in general payments reported to CMS, 2019-2025
21 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $570 · 2021: $567 · 2022: $451 · 2023: $473 · 2024: $754 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,289.71 | 2019-2025 | Dupixent |
| Optinose US, INC. | $439.52 | 2019-2024 | |
| Glaxosmithkline, LLC. | $421.64 | 2020-2025 | Nucala |
| Stryker Corporation | $307.43 | 2020-2021 | |
| Inspire Medical Systems, INC. | $290.68 | 2024-2025 | Inspire |
| Medtronic, INC. | $287.11 | 2021-2024 | Propel |
| Smith+Nephew, INC. | $210.68 | 2024-2025 | Coblation, Halo |
| Hologic Sales and Service, LLC | $144.45 | 2022 | |
| Genzyme Corporation | $141.25 | 2025 | |
| Resmed Corp | $53.76 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $50.21 | 2020-2021 | |
| Alk-Abello, INC | $46.09 | 2019-2021 | |
| Acclarent, INC | $36.34 | 2021 | |
| Kaleo, INC. | $33.28 | 2019-2021 | |
| Integra Lifesciences Corporation | $32.31 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.72 | 2021 | |
| Circassia INC. | $18.93 | 2019 | |
| Intersect Ent, INC. | $18.82 | 2019 | |
| Merck Sharp & Dohme LLC | $16.34 | 2023 | |
| Hikma Pharmaceuticals USA | $16.05 | 2023 | Ryaltris |
| Neurent Medical Limited | $14.22 | 2025 | Neuromark System, Neuromark Radiofrequency Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wes Allison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.